《生命科学》 2021, 33(9): 1133-1142

膀胱癌FGFR3基因突变及靶向药物治疗研究进展

车文安^1,2 , 孙远东¹ , 谭志林² , 陈　巍^2,* , 黄卫人^2,*

¹湖南科技大学，湘潭 411201 ²深圳市第二人民医院医学合成生物学 临床应用关键技术国家地方联合工程实验室，深圳 518036

摘　要：

膀胱癌是泌尿系统常见的恶性肿瘤，目前治疗手段多为外科手术治疗辅以化疗，但当前的化疗方案存在不足。成纤维细胞生长因子受体3 (fibroblast growth factor receptor 3, FGFR3) 属于酪氨酸激酶受体家族，是膀胱癌中最常见的突变基因之一。研究表明，该基因突变可作为膀胱癌治疗的靶点。该文概述膀胱癌中常见的 FGFR3 基因突变及相关信号通路的改变，总结了针对 FGFR3 的靶向药物的研究进展。

通讯作者：陈　巍 , Email:jessie_chenwei@163.com 黄卫人 , Email:pony8980@163.com

Research progress on FGFR3 mutations and targeted therapy in bladder cancer

CHE Wen-An^1,2 , SUN Yuan-Dong¹ , TAN Zhi-Lin² , CHEN Wei^2,* , HUANG Wei-Ren^2,*

¹Hunan University of Science and Technology, Xiangtan 411201, China ²State and Local Government Joint Engineering Laboratory of Synthetic Biology Medicine and Clinical Application of Key Technologies, Shenzhen Second People’s Hospital, Shenzhen 518036, China

Abstract:

Bladder cancer (BC) is one of the common malignant neoplasms of the urinary system, the most common treatment of which is surgical resection combined with chemotherapy. However, the current chemotherapy regimen is insufficient. Fibroblast growth factor receptor 3 (FGFR3) belongs to the receptor tyrosine kinase protein superfamily and is the most frequently mutated gene in bladder cancers. Researches have shown that FGFR3 is a promising therapeutic target in bladder cancer. In this review, we mainly discuss the FGFR3 mutations and related abnormalities of signaling pathways in bladder cancers, and recent progress on the development of FGFR3-targeted therapies.

Communication Author：CHEN Wei , Email:jessie_chenwei@163.com HUANG Wei-Ren , Email:pony8980@163.com